Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose
An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose to Healthy Male Subjects
Sponsor: Enyo Pharma
Listed as NCT04037618, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Enyo Pharma, it has been updated 6 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
▶ Show 1 earlier version
-
Aug 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Enyo Pharma
For direct contact, visit the study record on ClinicalTrials.gov .